ABP Key Statistics, Chart & Performance
The current stock price of ABP is 3.5 USD. In the past month the price decreased by -26.78%. In the past year, price decreased by -91.03%.
ABP Technical Analysis
ABP Financial Highlights
Over the last trailing twelve months ABP reported a non-GAAP Earnings per Share(EPS) of -24.37. The EPS decreased by -362.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1294.3% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ABP Forecast & Estimates
ABP Ownership
ABP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About ABP
Company Profile
ABPRO Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. Abpro Holdings, Inc. is a biotechnology company. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Company Info
ABPRO HOLDINGS INC
6 St Johns Lane, Floor 5
New York City NEW YORK US
Employees: 6
Phone: 12488907200
ABPRO HOLDINGS INC / ABP FAQ
What does ABP do?
ABPRO Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. Abpro Holdings, Inc. is a biotechnology company. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
What is the stock price of ABPRO HOLDINGS INC today?
The current stock price of ABP is 3.5 USD. The price decreased by -1.69% in the last trading session.
Does ABPRO HOLDINGS INC pay dividends?
ABP does not pay a dividend.
What is the ChartMill technical and fundamental rating of ABP stock?
ABP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of ABP stock?
ABPRO HOLDINGS INC (ABP) operates in the Health Care sector and the Biotechnology industry.